Table 2 Univariate and multivariate analyses of overall survival (OS), progression-free survival (PFS) and distant-metastasis-free survival (DMFS) in patients with NPC

OS

Gender (male vs. female)

1.207

0.389–3.746

0.745

Age (≥44 vs.<44)

2.418

0.839–6.971

0.102

EBV-DNA copy (4000>vs. ≤4000)

1.124

0.408–3.095

0.821

EA/IgA (≥1:10 vs. <1:10)

1.206

0.343–4.234

0.770

VCA/IgA (≥1:80 vs. <1:80)

1.104

0.25–4.876

0.896

T-stage (T3–4 vs. T1–2)

2.256

0.642–7.926

0.205

N-stage (N2–3 vs. N0–1)

0.647

0.235–1.784

0.400

Clinical staging (III+IV vs. I+II)

2.74

1.064–7.079

0.037

3.033

1.278–7.197

0.012

EpCAM (high vs. low level)

1.008

1.001–1.014

0.018

1.01

1.003–1.016

0.003

PFS

Gender (male vs. female)

1.385

0.455–4.211

0.566

Age (≥44 vs. <44)

1.728

0.715–4.175

0.224

EBV-DNA copy (4000>vs. ≤4000)

0.934

0.350–2.489

0.891

EA/IgA (≥1:10 vs. <1:10)

0.986

0.324–2.997

0.980

VCA/IgA (≥1:80 vs. <1:80)

0.808

0.233–2.802

0.737

T-stage (T3–4 vs. T1–2)

2.621

0.758–9.061

0.128

N-stage (N2–3 vs. N0–1)

2.621

0.758–9.061

0.128

Clinical staging (III+IV vs. I+II)

3.336

1.343–8.287

0.009

3.117

1.314–7.394

0.010

EpCAM (high vs. low level)

1.008

1.003–1.014

0.005

1.01

1.003–1.016

0.003

DMFS

Gender (male vs. memale)

3.705

0.474–28.947

0.212

Age (≥44 vs. <44)

1.600

0.653–3.921

0.304

EBV-DNA copy (4000>vs. ≤4000)

1.487

0.453–4.875

0.513

EA/IgA (≥1:10 vs. <1:10)

0.735

0.195–2.771

0.650

VCA/IgA (≥1:80 vs. <1:80)

0.767

0.166–3.550

0.734

T-stage (T3–4 vs. T1–2)

4.818

0.616–37.675

0.134

N-stage (N2–3 vs. N0–1)

1.765

0.516–6.034

0.365

Clinical staging (III+IV vs. I+II)

18.823

2.423–146.215

0.005

14.252

1.828–111.123

0.011

EpCAM (high vs. low level)

1.012

1.004–1.021

0.003

1.011

1.002–1.019

0.014